 | • レポートコード：MRC2303K080 • 出版社/出版日：Mordor Intelligence / 2023年2月 • レポート形態：英文、PDF、115ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医薬品 |
| Single User | ￥712,500 (USD4,750) | ▷ お問い合わせ |
| Corporate License | ￥1,312,500 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Mordor Intelligence社の調査レポートでは、世界の肝炎治療薬市場規模が、予測期間中（2022年-2027年）、CAGR 3.5％で増大すると予測されています。本レポートでは、肝炎治療薬の世界市場を広く調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、疾患種類別（A型肝炎、B型肝炎、C型肝炎、D型肝炎、その他）分析、薬剤クラス別（インターフェロン、モノクローナル抗体、非構造化タンパク質5A（NS5A）阻害剤、ヌクレオチド類似体逆転写酵素阻害剤、その他）分析、地域別（アメリカ、カナダ、メキシコ、ドイツ、イギリス、フランス、イタリア、スペイン、中国、日本、インド、オーストラリア、韓国、中東、南アフリカ、ブラジル、アルゼンチン）分析、競争状況、市場機会・将来動向などについて調査・分析などの項目を掲載しています。並び、こちらのレポートには、Merck & Co. Inc.、Gilead Sciences Inc.、AbbVie Inc.、Bristol Myers Squibb Company、F Hoffmann-La Roche, Ltd、LAURUS Labs、Zydus Cadila、Hetero Healthcare Limited、NATCO Pharma Limited、Cipla Inc.、Johnson & Johnson、Bioconなどの企業情報が含まれています。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界の肝炎治療薬市場規模：疾患種類別 - A型肝炎における市場規模 - B型肝炎における市場規模 - C型肝炎における市場規模 - D型肝炎における市場規模 - その他疾患における市場規模 ・世界の肝炎治療薬市場規模：薬剤クラス別 - インターフェロンの市場規模 - モノクローナル抗体の市場規模 - 非構造化タンパク質5A（NS5A）阻害剤の市場規模 - ヌクレオチド類似体逆転写酵素阻害剤の市場規模 - その他肝炎治療薬の市場規模 ・世界の肝炎治療薬市場規模：地域別 - 北米の肝炎治療薬市場規模 アメリカの肝炎治療薬市場規模 カナダの肝炎治療薬市場規模 メキシコの肝炎治療薬市場規模 … - ヨーロッパの肝炎治療薬市場規模 ドイツの肝炎治療薬市場規模 イギリスの肝炎治療薬市場規模 フランスの肝炎治療薬市場規模 … - アジア太平洋の肝炎治療薬市場規模 中国の肝炎治療薬市場規模 日本の肝炎治療薬市場規模 インドの肝炎治療薬市場規模 … - 南米/中東の肝炎治療薬市場規模 南アフリカの肝炎治療薬市場規模 ブラジルの肝炎治療薬市場規模 アルゼンチンの肝炎治療薬市場規模 … ・競争状況 ・市場機会・将来動向 |
The hepatitis therapeutics market is projected to register a CAGR of 3.5% during the forecast period (2022-2027).
The impact of COVID-19 on health care services has had a substantial impact on the delivery of care and outcomes for patients with chronic diseases. Therefore, there has been a decline in the treatment, diagnosis, and follow-up of patients with hepatitis B and C, which has had a significant impact on the healthcare industry as a whole. Additionally, clinical trials of the drug have been reduced as more and more companies delay the start of most new courses in several countries. In addition, the COVID-19 epidemic has seen a decline in outpatient services for patients with chronic hepatitis, which also had a significant impact on overall market growth. The study, titled “The impact of COVID-19 on hepatitis services and civil society organizations” published in July 2021, stated that the COVID-19 pandemic affected hepatitis prevention, testing, treatment, and vaccination services globally. However, the resumption of elective care procedures worldwide is likely to boost the market’s growth to pre-pandemic levels in the near future.
The market may show rapid growth due to the growing incidence of hepatitis, growing government support for awareness of hepatitis diseases, and increased availability of highly technologically advanced medical products.
Hepatitis is an inflammation or inflammation of the liver. Hepatitis may be due to drugs, alcohol consumption, or other medical conditions affecting the liver. But in most cases, it is caused by a virus called viral hepatitis, and the most common types are hepatitis A, B, and C. Hepatitis B is very common and can lead to severe cirrhosis of the liver, which can be fatal. Some of the most common symptoms are anorexia nervosa, nausea and vomiting, fatigue, fever, nausea, and stomach pain. Some people may have light-colored bowel movements, dark urine, skin, or yellow eyes (jaundice). Liver diseases are classified as hepatitis A, B, C, D, and E. A different virus is responsible for each type of sexually transmitted disease. Hepatitis A is a serious, temporary disease, while hepatitis B, C, and D progressively persist. Hepatitis E is usually severe but can be especially dangerous for pregnant women. Hepatitis can be diagnosed by history and physical examination, liver function tests, blood tests, and ultrasound. Some of the complications of hepatitis B or C are chronic liver disease, cirrhosis, and liver cancer.
According to the Primary Care for Hepatitis B statistics update of 2020, in 2020, an estimated 222,559 people were living with chronic hepatitis B (CHB) infection in Australia, representing 0.9% of the population. It also reported that only 73% of people living with CHB in Australia are estimated to have been diagnosed. Thus, the increasing burden of hepatitis is propelling the growth of the market.
Additionally, in March 2021, Dicerna Pharmaceuticals and Roche commenced the Phase II combination trial of the investigational GalXC RNAi candidate, RG6346, for the treatment of chronic hepatitis B virus (HBV) infection. Therefore, such research and development activities in the market are expected to drive market growth.
Therefore, the increase in the prevalence of the hepatitis B virus, the promising pipeline for hepatitis drugs, and government-sponsored programs to encourage patients to accept hepatitis drugs are important driving factors in the hepatitis therapeutics market. However, stringent regulatory issues and poor reimbursement policies are likely to impede the market’s growth over the analysis period.
Hepatitis Therapeutics Market Trends
Hepatitis C Segment is Expected to Hold a Major Market Share in the Hepatitis Therapeutics Market
Hepatitis C is a liver disease caused by the hepatitis C virus. Hepatitis C can range from a mild to life-threatening illness. Acute hepatitis C occurs within the first six months after exposure to the hepatitis C virus, and chronic hepatitis C can develop into lifelong hepatitis C if left untreated. According to data published by the World Health Organization (WHO) in July 2021, an estimated 58 million people have chronic hepatitis C virus, and about 1.5 million new infections occur annually. According to the same source, the hepatitis C virus is a blood-borne pathogen, and the most common form of infection is exposure to small amounts of blood. This often happens with unsafe injections and unsafe health care.
The hepatitis C segment has a large market share in the hepatitis therapeutics market. It is expected to show a similar trend over the forecast period due to the high prevalence of hepatitis C in developing and developed regions, as well as the growing availability of effective drugs in the market. In addition, the introduction of several products by major players is expected to boost the segment’s growth. For example, in June 2021, Gilead Sciences, Inc. received approval from the United States Food and Drug Administration (FDA) for Epclusa (sofosbuvir/velpatasvir) for the treatment of chronic hepatitis C virus (HCV) in children under 3 years of age, whether the HCV genotype or severity of the liver disease.
Therefore, the above factors lead to significant growth, thus contributing to the segment’s growth.
North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period
Due to an increase in hepatitis B infections along with fatalities owing to hepatitis and an increase in the commercial availability of anti-inflammatory drugs in the region, North America is expected to hold a major market share in the hepatitis therapeutics market. According to information provided by the Center for Disease Control and Prevention in 2019, a total of 3,192 cases of acute hepatitis B were reported in the United States in 2019, resulting in an estimated 20,700 cases. Moreover, the data published in the report titled “Viral Hepatitis National Strategic Plan: 2021–2025” for the United States, updated in January 2021, stated that people who have underlying medical disorders, such as those who have chronic liver diseases like hepatitis B and C, may be more susceptible to developing severe illnesses from COVID-19. In addition, favorable reimbursement policies, high rates of improved access to health care, and the availability of well-functioning health care infrastructure also stimulate growth across the regional market on a large scale.
In addition, the presence of key market players, coupled with growing awareness programs and the introduction of the latest products in the region, is responsible for bolstering the market’s growth in the United States. For instance, in December 2021, the United States Food and Drug Administration approved PreHevbrio [Recombinant Vaccine] to prevent infections caused by all known minor hepatitis B virus (HBV) infections in adults.
In addition, a national strategic plan was launched by the United States Department of Health and Human Services in January 2021 to eradicate hepatitis. It included five main goals; objectives and strategies to achieve these goals; and indicators with measurable objectives for monitoring progress. Therefore, the introduction of such programs by the government will improve the treatment of hepatitis in the country.
Thus, due to the abovementioned factors, the studied market is expected to grow during the study period in the region.
Hepatitis Therapeutics Market Competitor Analysis
The hepatitis therapeutics market is competitive and consists of several major players. However, in terms of market share, only a few of the major players are currently dominating the market. Some of the leading market players include Merck & Co., Inc., Gilead Sciences, Inc., AbbVie Inc., Bristol Myers Squibb Company, F. Hoffmann-La Roche, Ltd., LAURUS Labs, Zydus Cadila, Hetero Healthcare Limited, NATCO Pharma Limited, and Cipla Inc.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalence of Viral Hepatitis
4.2.2 Favorable Government Support for Creating Awareness about Hepatitis
4.2.3 Increasing Availability of Technologically Advanced Therapeutic Products
4.3 Market Restraints
4.3.1 Stringent Regulatory Issues
4.3.2 Poor Reimbursement Policies
4.4 Industry Attractiveness – Porter’s Five Forces Analysis
4.4.1 Bargaining Power of Buyers/Consumers
4.4.2 Bargaining Power of Suppliers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (Market Size by Value – USD Million)
5.1 By Disease Type
5.1.1 Hepatitis A
5.1.2 Hepatitis B
5.1.3 Hepatitis C
5.1.4 Hepatitis D
5.1.5 Other Types
5.2 By Drug Class
5.2.1 Interferon
5.2.2 Monoclonal Antibody
5.2.3 Non-structural protein 5A (NS5A) Inhibitors
5.2.4 Nucleotide Analog Reverse Transcriptase Inhibitors
5.2.5 Nucleotide Analog NS5B Polymerase Inhibitors
5.2.6 Multi Class Combination
5.2.7 Others
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Merck & Co. Inc.
6.1.2 Gilead Sciences Inc.
6.1.3 AbbVie Inc.
6.1.4 Bristol Myers Squibb Company
6.1.5 F Hoffmann-La Roche, Ltd
6.1.6 LAURUS Labs
6.1.7 Zydus Cadila
6.1.8 Hetero Healthcare Limited
6.1.9 NATCO Pharma Limited
6.1.10 Cipla Inc.
6.1.11 Johnson & Johnson
6.1.12 Biocon
7 MARKET OPPORTUNITIES AND FUTURE TRENDS